Found: 31
Select item for more details and to access through your institution.
Histamine and Cytokine Therapy: Paper presented at the annual meeting of the Swedish Oncology Society, Stockholm, 1997.
- Published in:
- Acta Oncologica, 1998, v. 37, n. 4, p. 347, doi. 10.1080/028418698430566
- By:
- Publication type:
- Article
Melflufen plus dexamethasone in relapsed/refractory multiple myeloma: long‐term survival follow‐up from the Phase II study O‐12‐M1.
- Published in:
- British Journal of Haematology, 2021, v. 193, n. 6, p. 1105, doi. 10.1111/bjh.17302
- By:
- Publication type:
- Article
Improved survival in myeloma patients: starting to close in on the gap between elderly patients and a matched normal population.
- Published in:
- British Journal of Haematology, 2014, v. 164, n. 5, p. 684, doi. 10.1111/bjh.12685
- By:
- Publication type:
- Article
Global Myeloma Research Clusters, Output, and Citations: A Bibliometric Mapping and Clustering Analysis.
- Published in:
- PLoS ONE, 2015, v. 10, n. 1, p. 1, doi. 10.1371/journal.pone.0116966
- By:
- Publication type:
- Article
A preseason booster prolongs the increase of allergen specific IgG4 levels, after basic allergen intralymphatic immunotherapy, against grass pollen seasonal allergy.
- Published in:
- Allergy, Asthma & Clinical Immunology, 2020, v. 16, n. 1, p. 1, doi. 10.1186/s13223-020-00427-z
- By:
- Publication type:
- Article
Epidemiology and clinical outcomes of light-chain amyloidosis in Sweden: A nationwide population-based study.
- Published in:
- European Journal of Haematology, 2023, v. 111, n. 5, p. 697, doi. 10.1111/ejh.14063
- By:
- Publication type:
- Article
Autoimmune disease is associated with a lower risk of progression in monoclonal gammopathy of undetermined significance.
- Published in:
- European Journal of Haematology, 2021, v. 106, n. 3, p. 380, doi. 10.1111/ejh.13563
- By:
- Publication type:
- Article
Outcome and characteristics of non‐measurable myeloma: A cohort study with population‐based data from the Swedish Myeloma Registry.
- Published in:
- European Journal of Haematology, 2020, v. 104, n. 5, p. 376, doi. 10.1111/ejh.13351
- By:
- Publication type:
- Article
Effectiveness and infectious complications of BCMA T‐cell engagers in treating multiple myeloma: Real‐world evidence from Sweden.
- Published in:
- Cancer Medicine, 2024, v. 13, n. 8, p. 1, doi. 10.1002/cam4.7048
- By:
- Publication type:
- Article
Lenalidomide versus lenalidomide + dexamethasone prolonged treatment after second‐line lenalidomide + dexamethasone induction in multiple myeloma.
- Published in:
- Cancer Medicine, 2018, v. 7, n. 6, p. 2256, doi. 10.1002/cam4.1422
- By:
- Publication type:
- Article
Improved Survival for Multiple Myeloma in Denmark Based on Autologous Stem Cell Transplantation and Novel Drug Therapy in Collaborative Trials: Analysis of Accrual, Prognostic Variables, Selection Bias, and Clinical Behavior on Survival in More Than 1200 Patients in Trials of the Nordic Myeloma Study Group
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2010, v. 10, n. 4, p. 290, doi. 10.3816/CLML.2010.n.060
- By:
- Publication type:
- Article
Incidence, characteristics, and outcome of solitary plasmacytoma and plasma cell leukemia. Population-based data from the Swedish Myeloma Register.
- Published in:
- European Journal of Haematology, 2017, v. 99, n. 3, p. 216, doi. 10.1111/ejh.12907
- By:
- Publication type:
- Article
Melphalan 100 mg/m<sup>2</sup> with stem cell support as first relapse treatment is safe and effective for myeloma patients with long remission after autologous stem cell transplantation.
- Published in:
- European Journal of Haematology, 2011, v. 87, n. 2, p. 117, doi. 10.1111/j.1600-0609.2011.01634.x
- By:
- Publication type:
- Article
Incidence of chronic myeloproliferative disorders in the city of Göteborg, Sweden 1983–1992.
- Published in:
- European Journal of Haematology, 2000, v. 65, n. 4, p. 267, doi. 10.1034/j.1600-0609.2000.065004267.x
- By:
- Publication type:
- Article
Impact of endogenous thrombopoietin levels on the differential diagnosis of essential thrombocythaemia and reactive thrombocytosis.
- Published in:
- European Journal of Haematology, 1998, v. 61, n. 2, p. 119, doi. 10.1111/j.1600-0609.1998.tb01071.x
- By:
- Publication type:
- Article
Cyclophosphamide Plus Dexamethasone Is an Efficient Initial Treatment Before High-dose Melphalan and Autologous Stem Cell Transplantation in Patients With Newly Diagnosed Multiple Myeloma.
- Published in:
- Cancer (0008543X), 2008, v. 112, n. 1, p. 129, doi. 10.1002/cncr.23145
- By:
- Publication type:
- Article
Variants in ELL2 influencing immunoglobulin levels associate with multiple myeloma.
- Published in:
- Nature Communications, 2015, v. 6, n. 5, p. 7213, doi. 10.1038/ncomms8213
- By:
- Publication type:
- Article
Patient Confidence and Information Preferences During the Treatment Decision-making Process: Results From a Large Multiple Myeloma Patient Survey Across 12 Countries in Europe and Israel.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2023, v. 23, n. 5, p. e240, doi. 10.1016/j.clml.2023.02.010
- By:
- Publication type:
- Article
Pharmacogenetic study of the impact of ABCB1 single-nucleotide polymorphisms on lenalidomide treatment outcomes in patients with multiple myeloma: results from a phase IV observational study and subsequent phase II clinical trial.
- Published in:
- 2018
- By:
- Publication type:
- journal article
Oral ixazomib-dexamethasone vs oral pomalidomide-dexamethasone for lenalidomide-refractory, proteasome inhibitor-exposed multiple myeloma: a randomized Phase 2 trial.
- Published in:
- Blood Cancer Journal, 2022, v. 12, n. 1, p. 1, doi. 10.1038/s41408-021-00593-2
- By:
- Publication type:
- Article
Author Correction: Germline variants at SOHLH2 influence multiple myeloma risk.
- Published in:
- 2021
- By:
- Publication type:
- Correction Notice
Germline variants at SOHLH2 influence multiple myeloma risk.
- Published in:
- Blood Cancer Journal, 2021, v. 11, n. 4, p. 1, doi. 10.1038/s41408-021-00468-6
- By:
- Publication type:
- Article
Sequence variation at the MTHFD1L-AKAP12 and FOPNL loci does not influence multiple myeloma survival in Sweden.
- Published in:
- 2019
- By:
- Publication type:
- Letter
Patterns of hematologic malignancies and solid tumors among 37,838 first-degree relatives of 13,896 patients with multiple myeloma in Sweden.
- Published in:
- International Journal of Cancer, 2009, v. 125, n. 9, p. 2147, doi. 10.1002/ijc.24514
- By:
- Publication type:
- Article
The multiple myeloma risk allele at 5q15 lowers ELL2 expression and increases ribosomal gene expression.
- Published in:
- Nature Communications, 2018, v. 9, n. 1, p. 1, doi. 10.1038/s41467-018-04082-2
- By:
- Publication type:
- Article
Impact of age on survival after intensive therapy for multiple myeloma: a population-based study by the Nordic Myeloma Study Group.
- Published in:
- British Journal of Haematology, 2006, v. 133, n. 4, p. 389, doi. 10.1111/j.1365-2141.2006.06042.x
- By:
- Publication type:
- Article
Cytochalasin B triggers a novel pertussis toxin sensitive pathway in TNF-alpha primed neutrophils.
- Published in:
- BMC Cell Biology, 2004, v. 5, p. 21, doi. 10.1186/1471-2121-5-21
- By:
- Publication type:
- Article
Longitudinal minimal residual disease assessment in multiple myeloma patients in complete remission - results from the NMSG flow-MRD substudy within the EMN02/HO95 MM trial.
- Published in:
- 2022
- By:
- Publication type:
- journal article
European Perspective on Multiple Myeloma Treatment Strategies: Update Following Recent Congresses.
- Published in:
- Oncologist, 2012, v. 17, n. 5, p. 592, doi. 10.1634/theoncologist.2011-0391
- By:
- Publication type:
- Article
A Combination Regimen of Bortezomib, Cyclophosphamide and Betamethasone Gives Quicker, Better and More Durable Response than VAD/CyBet Regimens: Results from a Swedish Retrospective Analysis.
- Published in:
- Acta Haematologica, 2013, v. 130, n. 1, p. 7, doi. 10.1159/000345422
- By:
- Publication type:
- Article
The choice of serum‐free light chain analysis method could potentially have clinical consequences for myeloma patients.
- Published in:
- EJHaem, 2024, v. 5, n. 3, p. 455, doi. 10.1002/jha2.886
- By:
- Publication type:
- Article